Apnea, Hypoxia
Conditions
Keywords
backup ventilation, preterm infants, functional residual capacity, chronic lung disease
Brief summary
In this 2-phase cross-over study the investigators test the hypothesis that automated adjustment of the inspired oxygen with the combined use of synchronized noninvasive SpO2-sensitive and apnea-sensitive backup-ventilation (S-NIPPV) increases the time within the intended oxygen saturation range as compared to automated FiO2 adjustment alone.
Detailed description
This study will be a randomized-controlled clinical study with cross-over design of two treatment phases of 24h duration each (1. Automated FiO2-adjustment (SPO2C), 2. combined use of automated FiO2-adjustment and SpO2-sensitive/apnea-sensitive S-NIPPV (SPO2C + BU), see Figures 1 and 2). The investigators will study two patient groups of premature infants depending on the type of respiratory support at study time: One group, where the infants are on CPAP at study time, and another group of preterm infants who are already supported by nasopharyngeal IPPV at study time. Both studies will be sufficiently powered to show a significant treatment effect if it is present. Study infants will be recruited in the neonatal ICU of the children's hospital, University of Ulm and the neonatal ICU, University of Munich. Both NICU team have participated previously in clinical trials investigated new modes of mechanical ventilation using automated ventilation adjustment in the target population. Randomization of the sequence of the two study phases will be carried out using sealed envelopes. Infants will be changed to a specific ventilator device approved for clinical use in neonates in Germany (Sophie®-Respirator, Stephan Medizintechnik GmbH, Gackenbach, Germany), which is capable to automatically adjust the FiO2 (called SPO2C) and to apply noninvasive backup-ventilation (using a noninvasive trigger device (S-NIPPV) or non-synchronized nasal IPPV (NIPPV) based on readings of an incorporated SpO2 monitoring device (Masimo® Radical 7, averaging time 2 sec). Synchronization of NIPPV and detection of apnea is achieved by using the Graseby capsule (Stephan, Vio Healthcare Ltd, Ref. 103560103), which will be secured onto the anterior abdominal wall near to the right costal margin. Infants on CPAP (first group) will be exposed to the first study phase (SPO2C, or SPO2C + BU, Figure 1) for 24h and then will be switched to the alternate mode for 24h each. Infants, who are already on nasal IPPV (SIPPV or NIPPV) as chosen by the clinical team will be exposed to NIPPV with a standardized inflation rate of 40 breaths/min (nonsynchronized, because this seems to be the current standard of care according to the available literature) and SPO2C, or to SPO2C plus synchronized BU (starting with a rate of 80 inflations/min with stepwise weaning) and then will be switched to the alternate mode for 24h each.
Interventions
DEVICESaturation sensitive backup ventilation
Sponsors
Dr. von Hauner Children's Hospital
University of Ulm
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
96 Hours to 34 Weeks
Healthy volunteers
Yes
Inclusion criteria
1. postmenstrual age \<34 wks GA at study time (\<32 wks GA at birth) 2. on nasal/nasopharyngeal CPAP or nasal IMV / IPPV 3. at least 4 desaturations (SpO2 \<80%) during an 8 hour period within the 24h before the study using a standard pulse oximeter incorporated in the NICU (Masimo SET, Irvine, CA, averaging time 8 sec; delay 10s) 4. informed consent obtained from the parents or legal guardian
Exclusion criteria
1. postnatal age \<96h (to exclude rapidly changing conditions during the early phase of RDS and to avoid handling of the infant during the critical period for IVH) 2. congenital cyanotic heart disease 3. no decision for full treatment support 4. Average FiO2 during the last 24h bevor the active study phase \>0.60 (too sick for non-invasive ventilator support) 5. Congenital malformations of the lung or the diaphragm (i.e. diaphragmatic hernia, congenital cystic lung diseases...) 6. Clinical evidence for seizures 7. Ongoing Sepsis with hemodynamic compromise (defined as a CrP \> 20mg/l or positive blood culture (for sepsis), and requirement of catecholamines (for hemodynamic compromise)) 8. Need of blood-transfusion during study time
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary outcome measure is the total duration of time with an arterial oxygen saturation as measured by pulse oxymetry (percentage of the total recording time) within the target range (88-95%). | 48 hours |
Secondary
| Measure | Time frame |
|---|---|
| Mean SpO2. | 48 hours |
| Mean FiO2 during the study time | 48 hours |
| The workload for the medical staff as measured by the number of manual adjustments of FiO2 because of episodes of hyperoxemia | 48 hours |
| The workload for the medical staff as measured by the number of manual adjustments of FiO2 because of episodes of hypoxemia. | 48 hours |
| Tissue oxygenation measurement (measured with near infrared spectrometry) of different organs (kidney, brain, muscle ) | 48 hours |
| the number of episodes with an SpO2 <80% | 48 hours |
| The number of extended/very long episodes outside the SpO2 target range (defined as episodes with a duration of more than 1 minute/3 minutes) | 48 hours |
| Variability of SpO2 (coefficient of variation) | 48 hours |
Other
| Measure | Time frame |
|---|---|
| the mean duration of episodes with an SpO2 with hyperoxemia (SpO2 >96%). | 48hours |
| The mean duration of episodes with an SpO2 <80% | 48 hours |
| the number of episodes with an SpO2 <80%. | 48hours |
| the number of episodes with an SpO2 <70%. | 45hours |
Outcome results
None listed